ACMG - American College of Medical Genetics and Genomics’ Post

In a special feature by #ONCOLife, Christine Roth, Executive Vice President at Bayer | Oncology, unveils the company's sophisticated approach towards advancing #cancer treatment. 🎯 Focusing on Precision Medicine: Roth discusses Bayer's targeted strategy in developing small molecules and #radiopharmaceuticals, particularly highlighting their efforts in combating #gastrointestinal and #prostatecancers. 🌐 Explore the full interview for a deeper understanding of how Bayer #Oncology is shaping the future of #cancertherapy. #CancerResearch To access the full version of the issue: https://lnkd.in/dEPMX98b

Very important paper to read.

For the folk’s interested in targeting MTAP homozygous deletions - this is an excellent dataset to get a reliable patient count / provided the algorithm to call homozygous deletions is fully reliable

- The Cancer Programme was part of the 100,000 Genomes Project focusing on whole-genome sequencing (WGS) for cancer patients within the UK. - Genomics England and NHS England analyzed WGS data from 13,880 solid tumors covering 33 cancer types. - The analysis integrated genomic data with real-world treatment. - Incidence of somatic mutations varied across cancer types; for instance, glioblastoma multiforme exhibited 94% small variants and 58% copy number aberrations. - Sarcoma showed the highest occurrence of actionable structural variants (13%). - Homologous recombination deficiency was identified in 40% of high-grade serous ovarian cancer cases, with 30% linked to pathogenic germline variants. - Linking WGS and longitudinal clinical data allowed survival analysis, identifying cancer genes impacting prognosis and enhancing understanding of cancer genomics' effect on patient outcomes.

Interesting paper with further insights for precision oncology

The first report from the Cancer Programme of the 100,000 Genomes Project, published in Nature Medicine, presents whole-genome sequencing profiles of 13,880 solid tumors spanning 33 cancer types, combined with real-world clinical data, providing insights for precision oncology. Read the paper: https://lnkd.in/eUj3pKgA

Taste the Future: #AI, Precision Oncology, & Clinical Trials with Massive Bio at #ASCO24 – Innovation in Every Bite! We got over 25,000 pieces of them. Visit the Massive Bio booth #29137 for exclusive demos. When you savor or share one of these M&Ms, remember our mission to make cancer #ClinicalTrials trials accessible to every patient worldwide. Join us in transforming oncology research! #CancerResearch Selin Kurnaz, PhD | Çağatay M. Çulcuoğlu

We may be new to LinkedIn, but we've been publishing research for over a year! In our 2023 issue, we published 38 articles that were viewed over 28,000 times by people in more than 165 countries. This year we plan to continue expanding the reach and impact of critical research. Browse our first issue for articles on: - QoL assessment within publications of oncology trials - MRI as a screening tool for prostate cancer - Global trends in early-onset cancer ...And much more! Find the full issue, free to read, right here ⬇️ #BMJOncology #CancerResearch #CancerScreening #CancerTrends

Discover the transformative role of AI-driven spatial biomarkers in precision oncology in Inside Precision Medicine's latest article, 'Aiming AI at Cancer-Related Biomarkers,' featuring our very own Dr. Ken Bloom. Learn how these advancements are reshaping the next generation of cancer treatments. Read the full article written by Mike May : https://hubs.li/Q02kN0Ch0 #spatialbiology #digitalpathology #spatialbiomarkers #biomarkers #Dx #precisiononcology

How can AI revolutionize early detection and screening for breast cancer? 🤖💡 AI has the potential to significantly enhance breast cancer screening by improving accuracy, reducing false positives, and enabling early detection. This can lead to more personalized treatment plans and better outcomes for patients. Let's explore how AI-driven innovations are shaping the future of healthcare! Link to register: https://lnkd.in/gS2GebRJ Manuella Kyeremeh